Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We think differently about the underlying genetic causes of cancer. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care. We follow the science, wherever it takes us, in pursuit of the best medicines. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry – encompassing molecules and modalities designed to preferentially kill cancer cells, at every stage of disease.

Our medicines are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some countries, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. However, please note that in some countries we are not permitted to provide very much, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.

Patients are at the heart of everything we do. Through relentless innovation and a commitment to scientific discovery we are catalysing changes in the practice of medicine to transform the patient experience. By working with the community, we can empower patients and caregivers, and are able to evolve the way cancer is treated by accelerating the uptake of the latest advancements.

Through collaborations with researchers, academia, healthcare providers, governments, industry and scientific organisations, patients and their families, we are uncovering unique insights on how we can establish new standards of screening, diagnostics and treatment.

Making significant scientific and cancer care advancements requires courage, curiosity, collaboration, and a passion for learning which is why we encourage disruptive thinking where failure is an opportunity to learn. Our team shares a united vision and everything we do begins with the science and centres around patients. Our people are driven by our bold ambition and together we can grow and achieve excellence.

Our team doesn’t fit one mould and we foster an inclusive culture where diversity drives innovation and progress, by challenging assumptions and creating opportunities for new discoveries and creative solutions.

^{Veeva ID: Z4-30595}

^{Date of Prep: 3 February 2021}